Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment

• Status: Completed
• Trial end date: 2020-03-18
• Target enrollment: 0
• Participant gender: All

Summary

In this study, the outcomes of relapsed AML patients receiving DLIs and Bicanorm (Sodium bicarbonate) were analyzed including T cell metabolism and immune phenotype.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Freiburg

Criteria

Inclusion Criteria:

• confirmed AML relapse after allo-HCT

• patients receiving DLIs

• age ≥ 18 years

• written informed consent

• ability to understand the nature of the study and the study related procedures and to comply with them

Exclusion Criteria:

• age < 18 years

• lack of informed consent